Endocyte (ECYT) Announces Presentation of EC1456 and EC1169 Data at ESMO 2016
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/23/2024
- Futures tread higher as more earnings roll in
- JPMorgan is worried about further S&P 500 sell-off potential
- Oil falls back after robust EU data as Mideast tensions linger
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- SAP Q1 results fall short of Wall Street estimates as transformation kicks off
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Kroger (KR), Albertsons and C&S Wholesale Grocers Announce an Updated and Expanded Divestiture Plan
- Costar Group (CSGP) to Acquire Matterport (MTTR) for $5.50/sh Cash and Stock
- Jaguar Health (JAGX) Files $75M Mixed Shelf
- Apple (AAPL) PT Lowered to $210 at Morgan Stanley, 'We'd buy post-earnings weakness'
- Apple, PepsiCo, JetBlue fall premarket; Amazon, GM and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
Endocyte Presents Data on Two Lead Clinical Programs at European Society for Medical Oncology (ESMO) 2016 Congress
October 10, 2016 8:00 AM EDTWEST LAFAYETTE, Ind., Oct. 10, 2016 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ: ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, presented poster updates on its two lead clinical programs at the European Society for Medical Oncology (ESMO) 2016 Congress, being held in Copenhagen, Denmark October 7-11, 2016.
We are pleased that both EC1456 and EC1169 have shown anti-tumor activity during the dose escalation phase of their respective trials, even in patients not specifically identified as positive for the drug targets, said Mike Sherman,... More
